Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

PSA/PSMA/PSCA-encoding DNA plasmid vaccine PF-06755990

A DNA vaccine consisting of plasmids encoding the tumor-associated antigens (TAAs) human prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA) and prostate stem cell antigen (PSCA), with potential immunostimulating and antineoplastic activities. Upon administration via intramuscular electroporation, the PSA/PSMA/PSCA-encoding DNA Plasmid Vaccine PF-06755990 expresses PSA, PSMA and PSCA, which may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells that are expressing PSA, PSMA and PSCA, resulting in tumor cell lysis. PSA, PSMA and PSCA are overexpressed on a variety of cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:PSA/PSMA/PSCA-encoding pDNA vaccine PF-06755990
Code name:PF 06755990
PF-06755990
PF06755990
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search